Merger and Acquisition - The Company entered into a Merger Agreement with Exascale, with a total Merger Consideration of $500,000,000, payable in the form of 50,000,000 newly issued shares valued at $10.00 per share[89][90]. Financial Performance - As of December 31, 2025, the Company reported a net income of $4,455,970, consisting of formation and operating costs of $320,658 and interest earned on cash held of $4,776,628[92]. - The Company completed its IPO on August 1, 2025, raising gross proceeds of $250,000,000 from the sale of 25,000,000 Units at $10.00 per Unit[95]. - The underwriters exercised a partial over-allotment option, purchasing an additional 3,000,000 units for gross proceeds of $30,000,000[97]. - As of December 31, 2025, the Company had $420,340 in cash and a working capital of $585,863[94]. - The Company incurred offering costs of $3,582,634 related to the Initial Public Offering[111]. Equity and Financing - The Company has 28,000,000 Class A ordinary shares subject to possible redemption, which are classified as temporary equity[109]. - The Company has no long-term debt or off-balance sheet financing arrangements as of December 31, 2025[101][102]. Future Plans and Costs - The Company expects to incur significant costs in pursuing its initial Business Combination and does not guarantee the success of these plans[88]. - The Company intends to use funds held outside of the Trust Account for identifying and evaluating prospective acquisition candidates and related due diligence[98].

Financial Performance - Aprea reported a net loss of $2.5 million ($0.32 per basic share) for Q4 2025, an improvement from a net loss of $2.9 million ($0.49 per basic share) in Q4 2024[12]. - For the full year 2025, Aprea reported a net loss of $12.6 million ($1.93 per basic share), compared to a net loss of $13.0 million ($2.35 per basic share) in 2024[12]. - Net loss for the year ended December 31, 2025, was $12,599,569, compared to a net loss of $12,958,711 in 2024, indicating a 2.8% improvement[21]. - The net loss per share attributable to common stockholders for 2025 was $1.93, compared to $2.35 in 2024, reflecting an improvement of approximately 17.9%[21]. Cash and Assets - Cash and cash equivalents as of December 31, 2025, were $14.6 million, down from $22.8 million as of December 31, 2024[14]. - Total assets decreased from $23,979,493 in 2024 to $15,933,401 in 2025, a decline of approximately 33.5%[20]. - Total stockholders' equity decreased from $19,307,455 in 2024 to $12,441,682 in 2025, a decline of approximately 35.4%[20]. - The number of common shares outstanding increased from 5,481,055 in 2024 to 8,192,538 in 2025, an increase of about 49.4%[20]. Revenue and Expenses - Grant revenue for the year ended December 31, 2025, was $285,759, down from $1,502,581 in 2024, representing an 81% decrease[21]. - Total operating expenses decreased from $15,822,236 in 2024 to $13,519,595 in 2025, a reduction of about 14.5%[21]. - Research and development expenses for the year ended December 31, 2025, were $7,043,035, down from $9,363,537 in 2024, a decrease of approximately 25%[21]. - General and administrative expenses increased slightly from $6,458,699 in 2024 to $6,476,560 in 2025, an increase of about 0.3%[21]. - General and Administrative (G&A) expenses for Q4 2025 were $1.6 million, up from $1.1 million in Q4 2024, mainly due to increased personnel costs[12]. Research and Development - Research and Development (R&D) expenses for Q4 2025 were $1.0 million, significantly lower than $2.4 million in Q4 2024, primarily due to reduced costs associated with clinical trials[12]. - The ongoing ACESOT-1051 trial of APR-1051 has shown early clinical proof-of-concept with two patients achieving unconfirmed partial responses[5]. - APR-1051 is being evaluated in patients with PPP2R1A mutations, with one patient showing a 50% reduction in target lesion size and a significant drop in CA-125 levels[6][7]. - Aprea plans to enrich patient enrollment in the ACESOT-1051 trial for endometrial, colorectal, and HPV+ tumors, with further updates expected in Q2 2026[11]. - The recommended Phase 2 dose for ATRN-119 was determined to be 1,100 mg for once daily dosing, with further enrollment paused to explore combination approaches[11]. Financing Activities - Aprea completed two private placements in December 2025 and January 2026, raising gross proceeds of approximately $3.1 million and $5.6 million, respectively[11].

Revenue and Financial Performance - Agenus recognized approximately $4.2 million in net revenue from early access programs in 2025, with $3.2 million in the fourth quarter alone[18]. - The company reported an operating loss of $20.2 million for the full year 2025[18]. Clinical Trials and Research - The BOT+BAL program achieved a 42% two-year overall survival rate and a median overall survival of approximately 21 months in heavily pretreated MSS mCRC patients[11]. - The BATTMAN Phase 3 registrational trial for BOT+BAL has been initiated, aiming to enroll approximately 830 patients across more than 100 sites in multiple countries[15][21]. - Clinical data from over 1,200 patients across nine tumor types support the potential of BOT+BAL as a next-generation immunotherapy[10][28]. Strategic Collaborations and Partnerships - A strategic collaboration with Zydus Lifesciences provided $91 million in upfront capital to strengthen Agenus' balance sheet and manufacturing capacity[16]. - The collaboration with Zydus includes a $20 million contingent payment triggered by initial BOT+BAL work orders[17]. Program Expansion and Global Reach - The early access programs have expanded globally, with over 200 physician inquiries from more than 30 countries[5][9]. - France's AAC program has expanded to include additional cancers, enhancing patient access to BOT+BAL[7]. Regulatory and Commercial Strategy - Agenus aims to advance regulatory filings in the U.S. and EU while strengthening its commercial readiness[23].

Financial Performance - Coya Therapeutics reported net losses of $21.2 million and $14.9 million for the years ended December 31, 2025, and 2024, respectively, with an accumulated deficit of $62.0 million as of December 31, 2025[20]. - The company expects to incur significant expenses and operating losses as it advances its product candidates through clinical trials and seeks regulatory approval[22]. - Coya's operations are primarily funded through the sale of securities, with plans to raise additional capital to support ongoing and future development[24]. Clinical Development - The company is conducting the ALSTARS Trial, a Phase 2 study for COYA 302 in ALS, with enrollment expected to complete in the second half of 2026[25]. - The FDA accepted the IND application for COYA 302 for both ALS and frontotemporal dementia (FTD), indicating progress in clinical development[27]. - COYA 302 is a biologic combination intended to enhance Treg function while depleting T effector function and activated macrophages[47]. - COYA 302 is also advancing for the treatment of FTD, with an IND accepted in January 2026[69]. - The anticipated developmental milestones include the acceptance of IND for COYA 302 in FTD in 1Q 2026 and the initiation of a Phase 2a study in 2H 2026[126]. Product Candidates - Coya plans to develop COYA 303, a new product candidate for inflammatory diseases, which has shown promising preclinical results in reducing pro-inflammatory responses[30]. - The company aims to leverage COYA 301 as a backbone for combination therapies targeting various neurodegenerative and autoimmune diseases[38]. - COYA 303, a new product candidate for inflammatory diseases, combines COYA 301 and a GLP-1 RA, showing significant immunomodulatory effects in preclinical studies[83]. - The Treg-derived exosome product candidate, COYA 201, is being developed with consistent batch-to-batch comparability and adequate long-term stability[117]. Clinical Study Results - Interim results from a proof of concept study for COYA 302 in FTD showed no serious adverse events and demonstrated enhanced Treg numbers and cognitive function stability[29]. - In a proof-of-concept study, ALS patients showed no decline or minimal decline in ALSFRS-R scores at 24 weeks (33.75 ±3.3) and 48 weeks (32 ±7.8) compared to baseline (33.5 ±5.9)[58]. - Treg suppressive function increased significantly during treatment, with values at 24 weeks (79.9±9.6) and 48 weeks (89.5±4.1) compared to baseline (62.1±8.1) (p<0.01)[61]. - The most common adverse event in the POC study was mild injection-site reactions, with no serious adverse events reported[67]. - The POC study in FTD showed no significant decline in cognitive function over 22 weeks, with MOCA scores remaining stable[77]. - The LD IL-2 q4wks treatment group showed a clinically meaningful improvement of 4.93 points in the ADAS-Cog14 score compared to placebo, indicating stabilization of cognitive function[95][101]. Regulatory Environment - Regulatory compliance is critical, with the FDA overseeing the approval process for biologics, requiring substantial time and financial resources for navigating preclinical and clinical trial requirements[137][140]. - The FDA must make a decision on accepting a BLA for filing within 60 days of receipt, which could include a refusal to file[152]. - The FDA targets ten months for the initial review of a new molecular entity NDA and six months for priority review[152]. - The company is subject to significant regulatory scrutiny, including compliance with FDA requirements and potential legal actions for non-compliance, which can lead to severe penalties[174]. - The company must comply with various federal and state laws targeting fraud and abuse, which could affect its sales and marketing strategies[189]. Market and Competitive Landscape - The competitive landscape includes various companies developing similar therapies for ALS and Treg-based cellular therapeutics, with some having greater financial resources and market experience[130][132]. - The company faces uncertainty regarding coverage and reimbursement for its product candidates, which can significantly impact sales in the U.S. market[177]. - The Inflation Reduction Act of 2022 mandates price negotiations for certain drugs under Medicare, with new prices for ten drugs starting in 2026 and another fifteen in 2027[186]. Intellectual Property and Exclusivity - The company licensed exclusive worldwide rights to a proprietary Exosome Engineering Technology from Carnegie Mellon University in September 2023, aimed at applications in neurodegeneration, autoimmune diseases, and oncology[122]. - The company may apply for patent term restoration of up to five years under the Hatch-Waxman Amendments, but cannot extend beyond a total of 14 years from the product's approval date[211]. - Recent litigation has created uncertainty regarding the ultimate effect, implementation, and meaning of the BPCIA exclusivity provisions[216].

Financial Performance - Fourth quarter revenues reached $35.7 million, a 10% increase compared to the same quarter in the previous year[4] - Transition period revenues totaled $75.5 million, reflecting a 20% increase from $63.0 million in the prior year[5] - Gross profit margin for the transition period improved to 31%, up from 26% in the previous year[5] - Adjusted EBITDA for the transition period was $13.1 million, significantly higher than $2.6 million in the prior year[8] - Total revenues for the three months ended December 31, 2025, were $35.747 million, an increase from $32.564 million in the same period of 2024, representing a growth of approximately 6.7%[33] - Adjusted EBITDA for the three months ended December 31, 2025, was $8.557 million, compared to $6.516 million for the same period in 2024, reflecting a year-over-year increase of approximately 31.2%[36] - The net loss for the year ended December 31, 2025, was $17.961 million, an improvement from a net loss of $30.638 million in 2024[33] - The company projects revenues for 2026 to be between $120,000,000 and $125,000,000, down from $141,432,000 in 2025[41] - The net loss for 2026 is estimated to be between $(33,400,000) and $(28,900,000), compared to $(26,040,000) in 2025[41] - Adjusted EBITDA for 2026 is expected to be between $20,500,000 and $25,000,000, down from $30,051,000 in 2025[41] Operating Efficiency - Operating expenses decreased by 31% to $24.4 million, down from $35.6 million in the prior year[5] - The company completed preparatory work for a new ERP system, launched in January 2026, to enhance operational efficiency[8] - Cash and cash equivalents increased to $17.469 million as of December 31, 2025, up from $8.265 million on May 25, 2025[31] - Total current assets decreased to $82.292 million as of December 31, 2025, compared to $85.677 million on May 25, 2025[31] - Operating cash flows for the year ending December 31, 2025, were $7,330,000, compared to $(5,593,000) for the previous year[38] - Free cash flow for the year ending December 31, 2025, was $3,634,000, a significant improvement from $(11,824,000) in the prior year[38] Growth Strategy - Lifecore aims for a 12% revenue CAGR from 2025 to 2029 and targets EBITDA margins above 25% in the mid-term[3] - The company aims to achieve a revenue CAGR of over 12% and increase Adjusted EBITDA margins to more than 25% in the mid-term[27] - The company has a three-pronged strategy for growth focusing on maximizing existing customer business, advancing late-stage development programs, and acquiring new impactful business[27] - Lifecore anticipates modest revenue growth in 2027, with significant growth expected in 2028 driven by customer program expansions[13] - Five new programs were signed during the transition period, including three in the fourth quarter[8] Research and Development - Research and development expenses for the three months ended December 31, 2025, were $2.297 million, up from $1.924 million in the same period of 2024[33] - Research and development expenses for 2026 are estimated at $9,300,000, up from $8,856,000 in 2025[41] Liabilities and Costs - The total liabilities as of December 31, 2025, were $198.117 million, an increase from $191.909 million on May 25, 2025[31] - The company incurred reorganization costs of $1,000,000 in 2026, compared to $5,787,000 in 2025[41] - Interest expense for 2026 is projected to be $31,000,000, an increase from $24,343,000 in 2025[41] Fiscal Year Transition - The company is transitioning to a December 31 fiscal year-end, which will provide a more meaningful year-over-year comparison[40] - The pro forma unaudited results for 2025 reflect a total revenue of $141,432,000, with a gross profit of $47,660,000[44]

Financial Performance - Coya Therapeutics reported a net loss of $21.2 million for the year ended December 31, 2025, compared to a net loss of $14.9 million for 2024, reflecting an increase of approximately 42%[11] - Net loss for 2025 was $21,226,107, compared to a net loss of $14,880,787 in 2024, indicating a significant increase in losses[23] - Net cash used in operating activities was $10,739,301 in 2025, slightly higher than $10,288,822 in 2024[23] Revenue and Collaboration - Collaboration revenues increased to $7.9 million in 2025 from $3.6 million in 2024, primarily due to a $3.6 million rise in license revenue[7] - Proceeds from the sale of common stock in 2025 amounted to $20,348,653, compared to $14,004,381 in 2024, showing a growth of about 45%[23] - Net cash provided by financing activities was $20,386,927 in 2025, an increase from $16,026,816 in 2024[23] Research and Development - Research and development (R&D) expenses rose to $16.7 million in 2025, up from $11.9 million in 2024, driven by increased clinical expenses related to COYA 302[8] - In-process research and development expenses were $2.3 million for 2025, compared to $0 for 2024, due to milestone payments related to the IND acceptance[9] - In-process research and development costs in accrued expenses were $1,125,000 in 2025, indicating ongoing investment in R&D[23] Cash and Assets - Coya had cash and cash equivalents of $46.8 million as of December 31, 2025, compared to $38.3 million at the end of 2024[6] - Cash and cash equivalents at the end of 2025 were $46,822,786, up from $38,339,762 at the end of 2024, representing an increase of approximately 22%[23] - The net increase in cash and cash equivalents for 2025 was $8,483,024, compared to $5,712,994 in 2024, reflecting improved cash flow management[23] - Coya's total assets increased to $49.95 million as of December 31, 2025, from $44.35 million in 2024[19] Expenses - General and administrative expenses increased to $11.4 million in 2025 from $8.9 million in 2024, primarily due to higher payroll and professional service fees[10] - Stock-based compensation increased to $4,290,315 in 2025 from $2,663,539 in 2024, reflecting a rise of approximately 61%[23] - The company incurred $1,164,602 in cash used for the purchase of in-process research and development assets in 2025, compared to $25,000 in 2024[23] Clinical Trials and Regulatory - Coya is actively enrolling patients in the ALSTARS Phase 2 trial for COYA 302 across approximately 25 clinical sites in the U.S. and Canada[2] - The company received FDA acceptance of its IND application for COYA 302 for the treatment of frontotemporal dementia (FTD)[2] Collaboration Receivables - The company reported a decrease in collaboration receivable from $7,500,000 in 2024 to $0 in 2025[23]

1 KE Holdings Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results and a Final Cash Dividend BEIJING, China, March 16, 2026 - KE Holdings Inc. ("Beike" or the "Company") (NYSE: BEKE; HKEX: 2423), a leading integrated online and offline platform for housing transactions and services, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025, and also announced a final cash dividend. Business and Financial Highlights for the Fourth ...

Business Segments and Operations - VEON's reportable segments include Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan, with operations in Kyrgyzstan reported separately under "Other"[30]. - Telecommunications and infrastructure revenues are generated from providing fixed and mobile services, emphasizing the core business operations of VEON[39]. Revenue Generation - The company measures "ARPU" (average revenue per user) by dividing mobile telecommunication and digital revenue by the average number of mobile customers, indicating a focus on revenue generation per user[32]. - "Direct digital revenue" encompasses various digital services, including entertainment, financial services, e-commerce, and enterprise solutions, highlighting the diversification of revenue streams[33]. - The total number of "Mobile customers" includes those engaged in revenue-generating activities, reflecting the company's active customer base[35]. - "Total Monthly Active Users" (MAU) represents the cumulative active users across all digital platforms, indicating user engagement levels[38]. Strategic Plans and Risks - Future plans include expanding 4G and 5G networks, broadband services, and integrated products, indicating a commitment to technological advancement and market growth[55]. - The company faces risks from geopolitical events, including the ongoing war in Ukraine, which may impact economic conditions and operational capabilities[51]. - The company aims to improve ARPU and manage future costs, reflecting a focus on financial performance and operational efficiency[55]. Data Sources - Market and industry data are sourced from reliable third-party studies, although not independently verified, indicating a reliance on external research for strategic decisions[40].

Clinical Trials and Efficacy - Obexelimab demonstrated a 56% reduction in the risk of IgG4-RD flare compared to placebo in the Phase 3 INDIGO trial, with a Hazard Ratio of 0.44 (p=0.0005) and met all key secondary endpoints [17]. - The Phase 2 MoonStone trial for relapsing multiple sclerosis (RMS) showed a 95% relative reduction in new gadolinium-enhancing lesions compared to placebo (p=0.0009) at the 12-week primary endpoint [18]. - Obexelimab has been evaluated in eight clinical trials with a total of 383 subjects, demonstrating a well-tolerated safety profile and clinical activity [29]. - In the IgG4-RD trial, 80% of patients showed a reduction in disease score, with 67% achieving complete remission [50]. - The Phase 2 trial of obexelimab in SLE showed a treatment difference of 17.3% in the ITT population (40.4% obexelimab vs. 23.1% placebo, p=0.06) [51]. - The Phase 2 trial of obexelimab for IgG4-RD included 20 patients, with 15 receiving 5 mg/kg IV every two weeks for 24 weeks [68]. - The Phase 2 trial showed that 21 out of 50 (42.0%) obexelimab-treated patients achieved the primary endpoint, although not statistically significant (p = 0.183) [100]. - Obexelimab demonstrated a 42.0% response rate in the EE population compared to 28.6% in the placebo group, with a treatment difference of 17.3% in the ITT analysis [100]. - The overall safety profile of obexelimab was favorable, with the majority of TEAEs being mild or moderate across multiple studies [107]. - The most common treatment-emergent adverse events included abdominal pain and nausea (20%), with no new safety signals observed at week 24 [76][79]. Product Development and Commercialization - The company plans to submit a Biologics License Application (BLA) for obexelimab to the FDA in Q2 2026 and a Marketing Authorization Application (MAA) to the EMA in the second half of 2026 [17]. - Each of the indications for obexelimab, including IgG4-RD, RMS, and systemic lupus erythematosus (SLE), represents a multi-billion-dollar commercial opportunity in the U.S. alone [16]. - The company has no product candidates approved for commercial sale and has not generated any revenue from product sales to date [25]. - The company plans to leverage initial successes to expand into broader I&I opportunities and evaluate strategic collaborations for commercialization [43]. - A recent licensing agreement secured rights to develop and commercialize orelabrutinib in MS worldwide, excluding greater China and Southeast Asia [43]. - The company plans to initiate a second Phase 3 trial for orelabrutinib in non-active SPMS in the first quarter of 2026, enrolling approximately 990 patients [140]. Intellectual Property and Licensing Agreements - The company owns or exclusively in-licenses 28 patent families covering various product candidates, with expiration dates ranging from 2027 to 2047 [194]. - The company has 14 patent families specifically covering obexelimab, with the first patent family expiring in May 2028 and others extending to October 2044 [197][198]. - The company entered into a License Agreement with InnoCare, making a one-time non-refundable upfront cash payment of $35.0 million and issuing 5,000,000 shares of common stock as partial consideration [185]. - The company received a one-time upfront payment of $50.0 million under the BMS Agreement, with potential milestone payments totaling up to $79.5 million for development and regulatory achievements, and up to $70.0 million for sales milestones [179]. - The last-to-expire patent under the BMS Agreement is set to expire on October 2, 2044, assuming all applications are allowed [180]. Future Developments and Pipeline - Orelabrutinib is being advanced in a Phase 3 trial for Primary Progressive Multiple Sclerosis (PPMS) and a second Phase 3 trial for non-active Secondary Progressive Multiple Sclerosis (SPMS) is expected to initiate in Q1 2026 [21]. - ZB021, an oral IL-17AA/AF inhibitor, is expected to initiate Phase 1 clinical studies in 2026, with initial data anticipated in 2027 [34]. - ZB022, a brain-penetrant TYK2-JH2 inhibitor, is in IND-enabling studies, with an IND application expected in 2026 [23]. - The company is also developing ZB014, an anti-CD-19 and FcγRIIb monoclonal antibody currently in pre-clinical studies [121]. Management and Strategy - The management team has extensive experience in biopharmaceuticals, having been responsible for numerous INDs and successful product launches [38]. - The strategy includes developing obexelimab for multiple I&I indications, with ongoing Phase 2 trials for RMS and SLE, and a Phase 3 trial for IgG4-RD [43].

Dividend and Stock Structure - NextEra has the right to increase the dividend rate on Series A preferred units to up to 20% per annum if not redeemed by November 29, 2025[317]. - There are no current plans to pay cash dividends on common stock for the foreseeable future, which may limit returns on investment unless shares are sold at a higher price[337]. - The dual-class structure of common stock allows Mr. Mark Comora to control 89.5% of voting power, limiting other stockholders' influence on corporate matters[329]. - The dual-class structure of the common stock may lead to lower or more volatile market prices for Class A common stock due to concentrated voting control by OPAL Holdco[336]. Financial Constraints and Capital Needs - The company may face significant financial constraints due to substantial debt service obligations, which could limit operational and growth opportunities[318]. - Future capital needs are expected to be significant, potentially leading to dilution of existing stockholders if additional Class A common stock is issued[320]. - The company may utilize project-level financing for future development, but obtaining such financing may not be guaranteed on favorable terms[319]. - Increased interest rates or reduced project debt financing could hinder the company's ability to construct and operate new projects[318]. Governance and Control Issues - The company is classified as a controlled company under Nasdaq rules, exempting it from certain corporate governance requirements[334]. - The potential for conflicts of interest exists due to family relationships among key executives, which may affect decision-making[333]. - Anti-takeover provisions in the certificate of incorporation could delay or prevent beneficial changes of control, impacting stockholder interests[338]. Market Risks and Volatility - The trading price of Class A common stock is likely to be volatile, influenced by factors such as financial results, market prices of oil and gas, and regulatory changes[342]. - A credit ratings downgrade could adversely affect the trading price of Class A common stock and the company's ability to access debt markets[345][346]. - The company is exposed to market risks related to commodity pricing and interest rates, employing strategies to hedge these risks through derivative transactions[474][475]. Regulatory and Operational Concerns - The company may lose its emerging growth status, which could subject it to more stringent regulatory requirements and affect investor confidence[326]. - Uncertainty regarding potential tariff increases could negatively impact operational costs, although no material adverse effect on cost of goods sold is currently anticipated[343][344]. - The company registered for resale up to 163,676,735 shares of Class A common stock, effective August 10, 2023, which may impact market price[322].